Mohammed Walid Chemao-Elfihri

Mohammed Walid Chemao-Elfihri

Auto-generated profile, based on publicly available information

Mohammed Walid Chemao-Elfihri

Mohammed VI University of Sciences and Health (UM6SS), Casablanca, Morocco

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
TATarek Alouane
Tarek Alouane
MLMeriem laamarti
Meriem laamarti
AEAbdelomunim Essabbar
Abdelomunim Essabbar
MHMohammed Hakmi
Mohammed Hakmi
EBEl mehdi Bouricha
El mehdi Bouricha
AIAzeddine IBRAHIMI
Azeddine IBRAHIMI
The COVID-19 pandemic has been ongoing since its onset in late November 2019 in Wuhan, China. Understanding and monitoring the genetic evolution of the virus, its geographical characteristics, and its stability are particularly important for controlling the spread of the disease and especially for the development of a universal vaccine covering all circulating strains. From this perspective, we analyzed 30,983 complete SARS-CoV-2 genomes from 79 countries located in the six continents and collected from 24 December 2019, to 13 May 2020, according to the GISAID database. Our analysis revealed the presence of 3206 variant sites, with a uniform distribution of mutation types in different geographic areas. Remarkably, a low frequency of recurrent mutations has been observed; only 169 mutations (5.27%) had a prevalence greater than 1% of genomes. Nevertheless, fourteen non-synonymous hotspot mutations (>10%) have been identified at different locations along the viral genome; eight in ORF1ab polyprotein (in nsp2, nsp3, transmembrane domain, RdRp, helicase, exonuclease, and endoribonuclease), three in nucleocapsid protein, and one in each of three proteins: Spike, ORF3a, and ORF8. Moreover, 36 non-synonymous mutations were identified in the receptor-binding domain (RBD) of the spike protein with a low prevalence (<1%) across all genomes, of which only four could potentially enhance the binding of the SARS-CoV-2 spike protein to the human ACE2 receptor. These results along with intra-genomic divergence of SARS-CoV-2 could indicate that unlike the influenza virus or HIV viruses, SARS-CoV-2 has a low mutation rate which makes the development of an effective global vaccine very likely.

3 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MLMeriem laamarti
Meriem laamarti
TATarek Alouane
Tarek Alouane
SKSouad Kartti
Souad Kartti
MCM.W. Chemao-Elfihri
M.W. Chemao-Elfihri
MHMohammed Hakmi
Mohammed Hakmi
AIAzeddine IBRAHIMI
Azeddine IBRAHIMI
In late December 2019, an emerging viral infection COVID-19 was identified in Wuhan, China, and became a global pandemic. Characterization of the genetic variants of SARS-CoV-2 is crucial in following and evaluating it spread across countries. In this study, we collected and analyzed 3,067 SARS-CoV-2 genomes isolated from 55 countries during the first three months after the onset of this virus. Using comparative genomics analysis, we traced the profiles of the whole-genome mutations and compared the frequency of each mutation in the studied population. The accumulation of mutations during the epidemic period with their geographic locations was also monitored. The results showed 782 variant sites, of which 512 (65.47%) had a non-synonymous effect. Frequencies of mutated alleles revealed the presence of 38 recurrent non-synonymous mutations, including ten hotspot mutations with a prevalence higher than 0.10 in this population and distributed in six SARS-CoV-2 genes. The distribution of these recurrent mutations on the world map revealed certain genotypes specific to the geographic location. We also found co-occurring mutations resulting in the presence of several haplotypes. Moreover, evolution over time has shown a mechanism of mutation co-accumulation which might affect the severity and spread of the SARS-CoV-2. On the other hand, analysis of the selective pressure revealed the presence of negatively selected residues that could be taken into considerations as therapeutic targets We have also created an inclusive unified database ( http://genoma.ma/covid-19/ ) that lists all of the genetic variants of the SARS-CoV-2 genomes found in this study with phylogeographic analysis around the world.

9 April 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
EFElmostafa El Fahime
Elmostafa El Fahime
SKSouad Kartti
Souad Kartti
MCMohammed Walid Chemao-Elfihri
Mohammed Walid Chemao-Elfihri
RFRihab FESTALI
Rihab FESTALI
MHMohammed Hakmi
Mohammed Hakmi
LBLahcen Belyamani
Lahcen Belyamani
Africa’s 1.5 billion people are underrepresented in genomic databases. The African Genome Variation Project exclusively focuses on Sub-Saharan populations, making Morocco, located in North Africa, a valuable site for studying genetic diversity. Understanding genetic variation and customized therapy requires population-specific reference genomes. This study presents Phase 1 results from the Moroccan Genome Project (MGP), which sequenced 109 Moroccan genomes. We report over 27 million variants, including 1.4 million novel ones, of which 15,378 are highly prevalent in the Moroccan population. Furthermore, we propose a Moroccan Major Allele Reference Genome (MMARG), generated using high-coverage consensus sequences from the 109 whole genomes. This MMARG represents more accurately the Moroccan genetic variation than GRCh38. This baseline study also generates an informative genetic variation database that supports regional population-specific initiatives and precision medicine in Morocco and North Africa. The results stress the necessity of population-relevant data in Human genetic research.

11 April 2025 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
MCMohammed Walid Chemao-Elfihri
Mohammed Walid Chemao-Elfihri
MHMohammed Hakmi
Mohammed Hakmi
HAHanane ABBOU
Hanane ABBOU
SKSouad Kartti
Souad Kartti
EFElmostafa El Fahime
Elmostafa El Fahime
SBSaber Boutayeb
Saber Boutayeb

16 November 2022 in Antonie van Leeuwenhoek
Verified
Journal Article
Closed access
PDF file
MCMohammed Walid Chemao-Elfihri
Mohammed Walid Chemao-Elfihri
MHMohammed Hakmi
Mohammed Hakmi
AEAbdelmounim Essabbar
Abdelmounim Essabbar
AMAmina Manni
Amina Manni
MLMeriem Laamarti
Meriem Laamarti
AFAbdelkarim Filali-Maltouf
Abdelkarim Filali-Maltouf

1 October 2024 in Research Square
Verified
Preprint
Open access
PDF file
EFElmostafa El Fahime
Elmostafa El Fahime
SKSouad Kartti
Souad Kartti
MCMohammed Chemao-Elfihri
Mohammed Chemao-Elfihri
RFRihab FESTALI
Rihab FESTALI
MHMohammed Hakmi
Mohammed Hakmi
LBLahcen Belyamani
Lahcen Belyamani
Africa's 1.5 billion people are underrepresented in genomic databases. The African Genome Variation Project exclusively studied populations south of the Sahara, making Morocco, on Africa's northwest coast, a desirable genetic variety study site. Understanding genetic variation and customized therapy require population-specific reference genomes. This study presents Phase 1 results from the Moroccan Genome Project (MGP), which sequenced 109 Moroccan genomes. Of the 27 million variations we found, 1.4 million were unique and 15,378 were highly prevalent in Morocco. The first Moroccan Major Allele Reference Genome (MMARG) was built utilizing high-coverage consensus sequences from 109 whole genomes. The latter more accurately depicts Moroccan genetic variations than GRCh38. To support regional population-specific initiatives and precision medicine in Morocco and North Africa, this baseline research created a high-quality reference genome and genetic variation database. The results stress the necessity of population-relevant data in Human genetic research.